A study investigates suPAR levels predicting renal outcomes in patients with glomerulonephritis, suggesting its utility in risk assessment.
In patients with biopsy-proven primary GN, higher suPAR levels at biopsy independently predicted subsequent eGFR decline but not proteinuria change, supporting longitudinal suPAR assessment as a complementary tool for renal risk stratification.
No takes yet. Share an insight, caveat, or question.
Choi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: